Efficacy,safety and acceptance of Acarbose treatment under day-to-day c l!nlcal practice conditions:Post-Marketing Surveillance in Chinese type 2 diabetic patients
- VernacularTitle:阿卡波糖治疗在日常临床工作中的有效性、安全性和被接受程度——对中国2型糖尿病患者的阿卡波糖上市后监测(英文)
- Author:
Sheng-Ou SU
;
Jia-Jun ZHAO
;
Jin ZHANG
;
Da-Jin ZOU
;
Hong LI
;
Zheng-Yan SHENG
;
Gan-Xiong LIANG
;
harald landen
- Publication Type:Journal Article
- Keywords:
Acarbose;
Chinese/Asian population;
Glyceraic control;
Post-marketing surveillance;
Diabetes mellitus;
type 2
- From:
Chinese Journal of Endocrinology and Metabolism
2000;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this Post-Marketing Surveillance study was to assess efficacy,safety and acceptance of acarbose treatment in Chinese type 2 diabetic patients under day-to-day practice conditions.A total of 2 480 patients were enrolled by 231 physicians throughout China into an open,prospective,uncontrolled,non- randomised,multi-centre study.Main efficacy parameters were the changes in fasting and postprandial blood glucose concentrations as well as in HbA-(1C) levels after acarbose treatment.The majority of patients had been previously treated with other oral anti-diabetic medication or insulin and received concomitant anti-diabetics during the mean observation period of 13.5 weeks.Most patients started on a daily acarbose dose of 50 mg t.i.d. Acarbose treatment reduced fasting blood glucose concentrations by 56.1 mg/dl ( 18 mg/dl glucose = 1 mmol/L glucose) and 2h-postprandial values by 111.3 mg/dl over the study period.HbA-(1C) decreased by 1.9% and body weight by 0.9 kg.76 acarbose-relatod adverse events occurred;two patients experienced serious adverse events. The attending physicians assessed treatment efficacy as“very good”or“good”for 90.1% of the patients, tolcrability for 89.1% and acarbose acceptance for 87.1% of the patients.Acarbose is efficacious,safe and well accepted by Chinese type 2 diabetic patients under day-to-day routine conditions,both as anti-diabetic mono- therapy and in combination with other anti-dlabetic drugs.
